Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/172488
Title: | Combining sensitive crossmatch assays with donor/recipient human leukocyte antigen eplet matching predicts living-donor kidney transplant outcome |
Author: | Meneghini, Maria Melilli, Edoardo Martorell, Jaume Revuelta, Ignacio Rigol Monzó, Elisabet Manonelles, Anna Montero, Nuria Cucchiari, David Diekmann, Fritz Cruzado, Josep Ma. Gil-Vernet, Salvador Grinyó Boira, Josep M. Bestard Matamoros, Oriol |
Keywords: | Trasplantament renal Leucòcits Antígens Kidney transplantation Leucocytes Antigens |
Issue Date: | 2018 |
Publisher: | Elsevier |
Abstract: | Introduction: Despite the different assays available for immune-risk stratification before living-donor kidney transplantation (LDKT), the precise type and number of tests to perform remain uncertain. Methods: In a cohort of 330 consecutive LDKT patients, all of which were complement-dependent cyto- toxicity (CDC) crossmatch negative, we retrospectively analyzed the impact on main clinical outcomes of most sensitive immunoassays (complement-dependent cytotoxicity panel-reactive antibody [CDC-PRA], flow cytometry crossmatch [FC-XM], donor-specific antibodies [DSAs], and their complement-binding capacity DSA-C3d]), together with donor/recipient HLA eplet matching. Mean follow-up was 67 months (range 24 190 months). Results: Of 330 patients, 35 (11%) showed a CDC-PRA >20%; 17 (5%) FC-XMþ; 30 (9%) DSAþ, 18(5%) DSA- C3dþ, with low overlapping results (10 patients positive in all donor-specific tests). Unlike HLA allele compatibility, the mean number of HLA class II eplet mismatches was higher in LDKT patients with positive baseline test results. DSA-C3dþ showed higher mean fluorescence intensity (MFI) DSA, with a cut-off MFI of 6192 accurately predicting complement fixation (area under the curve 1⁄4 0.85, P 1⁄4 0.008). Although all assays were associated with acute rejection (AR), only DSA-C3dþ (odds ratio [OR] 1⁄4 6.64, P 1⁄4 0.038) or high MFI-DSA (OR 1⁄4 7.54, P 1⁄4 0.038) independently predicted AR. Likewise, poorly HLA class II eplet matched patients were at higher risk for AR, particularly patients with negative baseline test results (OR 1⁄4 1.14, P 1⁄4 0.019). Finally, previous AR and FC-XMþ/DSAþ, regardless of C3d positivity, indepen- dently predicted graft loss. Conclusion: Combining FC-XM and solid-phase assays with the evaluation of donor/recipient HLA eplet mismatches, are most accurate tools for immune-risk stratification prior LDKT. |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.ekir.2018.03.015 |
It is part of: | Kidney International Reports, 2018, vol. 3, num. 4, p. 926-938 |
URI: | https://hdl.handle.net/2445/172488 |
Related resource: | https://doi.org/10.1016/j.ekir.2018.03.015 |
ISSN: | 2468-0249 |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
682587.pdf | 1.41 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License